Individuals with BARD1 and BRCA1 germline pathogenic mutations have been found to have a higher incidence rates of aggressive breast cancer phenotypes, such as TNBCs, which are associated with higher rates of recurrence, progression, and mortality [31,32,33]. The gene discussed is BRCA1; the disease is breast carcinoma.